Key facts
- Epicore Biosystems’s last known valuation is $121.0M (May 2025).
- It has raised $43.1M across 4 recorded rounds; the latest was Early Stage VC ($25.7M) in Dec 2024.
- Notable investors include Alumni Ventures, Joyance Partners, Pegasus Tech Ventures, Reform Ventures, Chevron Technology Ventures — 13 tracked in total.
- Epicore Biosystems has filed 6 Form Ds with the SEC since 2018, most recently Apr 2025 ($25.7M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Epicore Biosystems
Funding rounds
4 roundsAbout Epicore Biosystems
Developer of a wearable microfluidic sensor technology designed to improve health and drive athletic performance. The company's sensors can non-invasively measure sweat biomarkers, skin health and physiology in real-time, enabling athletes to analyze small droplets of sweat directly from their skin at a low cost.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 35
- Website
- epicorebiosystems.com/
- Ownership
- Privately Held (backing)
Epicore Biosystems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epicore Biosystems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epicore Biosystems in its N-PORT filings yet. We sweep new filings monthly.